Global Market Study Biological Drugs: North America to Remain as the Largest Biological Drug Market during the Forecast Period (2014-2020)


#320651

152pages

Persistence Market Research

$ 4900

In Stock

Persistence Market Research (PMR) provides key insights on the global biological drugs market over the forecast period (2014-2020). The primary objective of the report is to provide in-depth analysis and future market estimations, including growth drivers, restraints, opportunities, trends, key segments, status of the regional markets and key market participants operating in the global scar treatment market. Along with the provision of quality insights quantification of data has been considered through discussions with market experts, clinicians and product managers.  

To understand and assess opportunities in the global marketplace, the report is categorically split into four sections in terms of market value (US$ Mn), namely market analysis by therapeutic protein type, by monoclonal antibody (mAb), by vaccine type and by geography. The report further provides comprehensive data on forecast values, global market estimations, and competitive landscape. The aforementioned segments have been analyzed in terms of Basis Point (BPS) to understand each segment’s relative contribution to the overall market growth. 

The geographical analysis studies the market on the basis of the regional opportunities and estimates the market value for each region during the forecast period. The report also considers a year-on-year growth based on regional market analysis, in order to identify right opportunities in each of the regions and to understand predictability of the market.

The last part of the report provides an exhaustive analysis on the global competitive landscape including leading market participants and a dashboard view. Market strategies of prominent players and their key developments have also been included in the report. 

Research Methodology

To deduce the global biological drugs market, the report considers various aspects based on secondary research. Furthermore, key data points such as region-wise split and market split by therapeutic protein type, by monoclonal antibody (mAb), by vaccine type and qualitative inputs from primary respondents have been incorporated to arrive at appropriate market estimates. The forecast presented in the report assesses the total revenue generated and expected revenue contribution in the global biological drugs market.    

The report begins with sizing the market in terms of value and volume for the base year, which forms the basis for forecasting how the market is anticipated to take shape in the near future. Given the characteristics of the market, gathered data is triangulated via different analysis based on the supply side and demand side drivers and other key dynamics of the global biological drugs market. To develop the market forecast, Persistence Market Research has also conducted a factor analysis to understand the impact of various forces/factors on the target market. The report provides forecasts not only in terms of CAGR but also presents a detailed analysis based on key parameters such as Year-on-Year (Y-o-Y) growth to understand market predictability and to identify the right opportunities.     

Another key feature of this report is an analysis of the global biological drugs market and the corresponding revenue forecast in terms of absolute dollar opportunity, usually overlooked while forecasting the market. However, absolute dollar opportunity is critical in assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales perspective in the biological drugs devices market. Further, to understand key segments in terms of their growth and overall global biological drugs market performance, Persistence Market Research has developed a market attractiveness index to help providers identify existing market opportunities in the global biological drugs market.

Some of the major players in the biological drugs market:

  • Pfizer Inc.
  • Abbott Laboratories.
  • Novartis AG.
  • Eli Lilly and Company.
  • GlaxoSmithKline plc.
  • Bristol-Myers Squibb Company.
  • Merck & Co., Inc.
  • Amgen Inc.
  • Baxter International Inc.
  • Biogen Idec.
  • Other

These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability, and financial overview.

Table of Content

Chapter 1 Preface 11
1.1 Report Description 11
1.2 Report Methodology 12
1.3 Assumptions 12


Chapter 2 Market Synopsis 13


Chapter 3 Porter’s Five Forces Analysis 14
3.1 Bargaining power of suppliers 14
3.2 Bargaining power of buyers 15
3.3 Threat of new entrants 15
3.4 Threat of substitutes 15
3.5 Intensity of rivalry 15


Chapter 4 Industry Overview 17
4.1 Market Definition 17
4.2 Market Drivers 18
4.2.1 Increasing prevalence of chronic diseases 18
4.2.2 Growing geriatric population 19
4.2.3 Rising initiatives by various government associations 20
4.3 Impact Analysis of Market Drivers 21
4.4 Market Restraints 21
4.4.1 High costs of biological drugs 21
4.4.2 Patent expiration of various blockbuster biological drugs 22
4.4.3 Risk of adverse effects associated with biological injectable medicines 22
4.5 Impact analysis of Market Restraints 23
4.6 Opportunities 24
4.6.1 Advancements in biomedical science 24
4.7 Market Trends 24
4.7.1 VEGF therapy is gaining popularity in the biopharmaceutical industry 24
4.7.2 GMOs are gaining importance in the biological drugs market 25


Chapter 5 Global Market Size And Forecast 26


Chapter 6 Market Size and Forecast by Therapeutic Protein 30
6.1 Enbrel 30
6.2 Lantus 33
6.3 Neulasta 35
6.4 Avonex 37
6.5 NovoLog 40
6.6 Rebif 42
6.7 Humalog 44
6.8 Aranesp 46
6.9 Epogen 48
6.10 Levemir 50
6.11 Victoza 52
6.12 Betaseron 54
6.13 Neupogen 56
6.14 Eylea 58


Chapter 7 Market Size and Forecast by mAb 60
7.1 Humira 60
7.2 Remicade 63
7.3 Rituxan 65
7.4 Avastin 67
7.5 Herceptin 70
7.6 Lucentis 72


Chapter 8 Market Size and Forecast by Vaccine 74
8.1 Prenvar 13 74
8.2 Gardasil 77
8.3 Fluzone 79
8.4 Varivax 81
8.5 Cervarix 83


Chapter 9 Market Size and Forecast by Geography 85
9.1 North America 85
9.2 Europe 94
9.3 Asia 103
9.4 Rest of the World (RoW) 112


Chapter 10 Pipeline Biological Drugs 113
10.1 Biological drugs under development for auto-immune diseases 113
10.2 Biological drugs under development for blood diseases 114
10.3 Biological drugs under development for cancer and related conditions 115
10.4 Biological drugs under development for diabetes and cardiovascular diseases 116


Chapter 11 Competitive Scenario 117
11.1 Competitive Benchmarking 117


Chapter 12 Company Profiles 118
12.1 Pfizer Inc. 118
12.1.1 Company Overview 118
12.1.2 Product and Services 119
12.1.3 Financial Performance 119
12.1.4 Recent Developments 120
12.2 Abbott Laboratories 122
12.2.1 Company Overview 122
12.2.2 Product and Services 123
12.2.3 Financial Performance 124
12.2.4 Recent Developments 124
12.3 Novartis AG 125
12.3.1 Company Overview 125
12.3.2 Product and Services 126
12.3.3 Financial Performance 127
12.3.4 Recent Developments 127
12.4 Eli Lilly and Company 129
12.4.1 Company Overview 129
12.4.2 Product and Services 129
12.4.3 Financial Performance 130
12.4.4 Recent Developments 130
12.5 GlaxoSmithKline plc. 131
12.5.1 Company Overview 131
12.5.2 Product and Services 131
12.5.3 Financial Performance 132
12.5.4 Recent Developments 132
12.6 Bristol-Myers Squibb Company 135
12.6.1 Company Overview 135
12.6.2 Product and Services 135
12.6.3 Financial Performance 136
12.6.4 Recent Developments 136
12.7 Merck & Co., Inc. 139
12.7.1 Company Overview 139
12.7.2 Product and Services 139
12.7.3 Financial Performance 140
12.7.4 Recent Developments 140
12.8 Amgen Inc. 142
12.8.1 Company Overview 142
12.8.2 Product and Services 142
12.8.3 Financial Performance 143
12.8.4 Recent Developments 143
12.9 Baxter International Inc. 145
12.9.1 Company Overview 145
12.9.2 Product and Services 145
12.9.3 Financial Performance 146
12.9.4 Recent Developments 146
12.10 Biogen Idec 149
12.10.1 Company Overview 149
12.10.2 Product and Services 149
12.10.3 Financial Performance 150
12.10.4 Recent Developments 15

TABLE 1 Market snapshot: Global market for biological drugs (2014 & 2020) 13
TABLE 2 Major biological drugs and their applications 19
TABLE 3 Drivers for global biological drugs market: Impact analysis 21
TABLE 4 Major biological drugs and their adverse effects 23
TABLE 5 Restraints for global biological drugs market: Impact analysis 23
TABLE 6 Global market for biological drugs, by geography, 2009–2013 (US$ Mn) 26
TABLE 7 Global market for biological drugs, by geography, 2014–2020 (US$ Mn) 27
TABLE 8 Global market for biological drugs, by segment, 2009–2013 (US$ Mn) 28
TABLE 9 Global market for biological drugs, by segment, 2014–2020 (US$ Mn) 29
TABLE 10 Global market for Enbrel, by geography, 2009–2013 (US$ Mn) 31
TABLE 11 Global market for Enbrel, by geography, 2014–2020 (US$ Mn) 31
TABLE 12 Global market for Lantus, by geography, 2009–2013 (US$ Mn) 33
TABLE 13 Global market for Lantus, by geography, 2014–2020 (US$ Mn) 34
TABLE 14 Global market for Neulasta, by geography, 2009–2013 (US$ Mn) 35
TABLE 15 Global market for Neulasta, by geography, 2014–2020 (US$ Mn) 36
TABLE 16 Global market for Avonex, by geography, 2009–2013 (US$ Mn) 38
TABLE 17 Global market for Avonex, by geography, 2014–2020 (US$ Mn) 38
TABLE 18 Global market for NovoLog, by geography, 2009–2013 (US$ Mn) 40
TABLE 19 Global market for NovoLog, by geography, 2014–2020 (US$ Mn) 41
TABLE 20 Global market for Rebif, by geography, 2009–2013 (US$ Mn) 42
TABLE 21 Global market for Rebif, by geography, 2014–2020 (US$ Mn) 43
TABLE 22 Global market for Humalog, by geography, 2009–2013 (US$ Mn) 44
TABLE 23 Global market for Humalog, by geography, 2014–2020 (US$ Mn) 45
TABLE 24 Global market for Aranesp, by geography, 2009–2013 (US$ Mn) 46
TABLE 25 Global market for Aranesp, by geography, 2014–2020 (US$ Mn) 47
TABLE 26 Global market for Epogen, by geography, 2009–2013 (US$ Mn) 48
TABLE 27 Global market for Epogen, by geography, 2014–2020 (US$ Mn) 49
TABLE 28 Global market for Levemir, by geography, 2009–2013 (US$ Mn) 50
TABLE 29 Global market for Levemir, by geography, 2014–2020 (US$ Mn) 51
TABLE 30 Global market for Victoza, by geography, 2009–2013 (US$ Mn) 52
TABLE 31 Global market for Victoza, by geography, 2014–2020 (US$ Mn) 53
TABLE 32 Global market for Betaseron, by geography, 2009–2013 (US$ Mn) 54
TABLE 33 Global market for Betaseron, by geography, 2014–2020 (US$ Mn) 55
TABLE 34 Global market for Neupogen, by geography, 2009–2013 (US$ Mn) 56
TABLE 35 Global market for Neupogen, by geography, 2014–2020 (US$ Mn) 57
TABLE 36 Global market for Eylea, by geography, 2009–2013 (US$ Mn) 58
TABLE 37 Global market for Eylea, by geography, 2014–2020 (US$ Mn) 59
TABLE 38 Global market for Humira, by geography, 2009–2013 (US$ Mn) 61
TABLE 39 Global market for Humira, by geography, 2014–2020 (US$ Mn) 61
TABLE 40 Global market for Remicade, by geography, 2009–2013 (US$ Mn) 63
TABLE 41 Global market for Remicade, by geography, 2014–2020 (US$ Mn) 64
TABLE 42 Global market for Rituxan, by geography, 2009–2013 (US$ Mn) 65
TABLE 43 Global market for Rituxan, by geography, 2014–2020 (US$ Mn) 66
TABLE 44 Global market for Avastin, by geography, 2009–2013 (US$ Mn) 68
TABLE 45 Global market for Avastin, by geography, 2014–2020 (US$ Mn) 68
TABLE 46 Global market for Herceptin, by geography, 2009–2013 (US$ Mn) 70
TABLE 47 Global market for Herceptin, by geography, 2014–2020 (US$ Mn) 71
TABLE 48 Global market for Lucentis, by geography, 2009–2013 (US$ Mn) 72
TABLE 49 Global market for Lucentis, by geography, 2014–2020 (US$ Mn) 73
TABLE 50 Global market for Prevnar 13, by geography, 2009–2013 (US$ Mn) 75
TABLE 51 Global market for Prevnar 13, by geography, 2014–2020 (US$ Mn) 75
TABLE 52 Global market for Gardasil, by geography, 2009–2013 (US$ Mn) 77
TABLE 53 Global market for Gardasil, by geography, 2014–2020 (US$ Mn) 78
TABLE 54 Global market for Fluzone, by geography, 2009–2013 (US$ Mn) 79
TABLE 55 Global market for Fluzone, by geography, 2014–2020 (US$ Mn) 80
TABLE 56 Global market for Varivax, by geography, 2009–2013 (US$ Mn) 81
TABLE 57 Global market for Varivax, by geography, 2014–2020 (US$ Mn) 82
TABLE 58 Global market for Cervarix, by geography, 2009–2013 (US$ Mn) 83
TABLE 59 Global market for Cervarix, by geography, 2014–2020 (US$ Mn) 84
TABLE 60 North America market for biological drugs, by country, 2009–2013 (US$ Mn) 86
TABLE 61 North America market for biological drugs, by country, 2014–2020 (US$ Mn) 87
TABLE 62 North America market for biological drugs, by therapeutic protein, 2009–2013 (US$ Mn) 88
TABLE 63 North America market for biological drugs, by therapeutic protein, 2014–2020 (US$ Mn) 89
TABLE 64 North America market for biological drugs, by mAb, 2009–2013 (US$ Mn) 90
TABLE 65 North America market for biological drugs, by mAb, 2014–2020 (US$ Mn) 91
TABLE 66 North America market for biological drugs, by vaccine, 2009–2013 (US$ Mn) 92
TABLE 67 North America market for biological drugs, by vaccine, 2014–2020 (US$ Mn) 93
TABLE 68 Europe market for biological drugs, by country, 2009–2013 (US$ Mn) 95
TABLE 69 Europe market for biological drugs, by country, 2014–2020 (US$ Mn) 95
TABLE 70 Europe market for biological drugs, by therapeutic protein, 2009–2013 (US$ Mn) 97
TABLE 71 Europe market for biological drugs, by therapeutic protein, 2014–2020 (US$ Mn) 98
TABLE 72 Europe market for biological drugs, by mAb, 2009–2013 (US$ Mn) 99
TABLE 73 Europe market for biological drugs, by mAb, 2014–2020 (US$ Mn) 100
TABLE 74 Europe market for biological drugs, by vaccine, 2009–2013 (US$ Mn) 101
TABLE 75 Europe market for biological drugs, by vaccine, 2014–2020 (US$ Mn) 102
TABLE 76 Asia market for biological drugs, by country, 2009–2013 (US$ Mn) 104
TABLE 77 Asia market for biological drugs, by country, 2014–2020 (US$ Mn) 104
TABLE 78 Asia market for biological drugs, by therapeutic protein, 2009–2013 (US$ Mn) 106
TABLE 79 Asia market for biological drugs, by therapeutic protein, 2014–2020 (US$ Mn) 107
TABLE 80 Asia market for biological drugs, by mAb, 2009–2013 (US$ Mn) 108
TABLE 81 Asia market for biological drugs, by mAb, 2014–2020 (US$ Mn) 109
TABLE 82 Asia market for biological drugs, by vaccine, 2009–2013 (US$ Mn) 110
TABLE 83 Asia market for biological drugs, by vaccine, 2014–2020 (US$ Mn) 111
TABLE 84 Some pipeline biological drugs for auto-immune diseases 113
TABLE 85 Some pipeline biological drugs for blood diseases 114
TABLE 86 Some pipeline biological drugs for cancer and related conditions 115
TABLE 87 Some pipeline biological drugs for diabetes and cardiovascular diseases 116
TABLE 88 Pfizer major product segments 119
TABLE 89 Abbott major product categories 123
TABLE 90 Novartis product segments 126
TABLE 91 Lilly product segments 129
TABLE 92 GlaxoSmithKline product segments 131
TABLE 93 Bristol-Myers Squibb key product and brands 135
TABLE 94 Merck key product categories 139
TABLE 95 Amgen product category 142
TABLE 96 Baxter major product categories 145
TABLE 97 Biogen Idec major therapies and their uses 149

FIG. 1 Biological drugs market: Porter’s five force analysis 14
FIG. 2 Biological drugs market, by therapeutic proteins, mAbs and vaccine 18
FIG. 3 Geriatric population in major countries, 2000–2050, (% share) 20
FIG. 4 Global market for biological drugs by geography 2013 (% share) 26
FIG. 5 Global market for biological drugs by segment 2013 (% share) 28
FIG. 6 Global market for Enbrel by geography 2013 (% share) 30
FIG. 7 Global market for Lantus by geography 2013 (% share) 33
FIG. 8 Global market for Neulasta by geography 2013 (% share) 35
FIG. 9 Global market for Avonex by geography 2013 (% share) 37
FIG. 10 Global market for NovoLog by geography 2013 (% share) 40
FIG. 11 Global market for Rebif by geography 2013 (% share) 42
FIG. 12 Global market for Humalog by geography 2013 (% share) 44
FIG. 13 Global market for Aranesp by geography 2013 (% share) 46
FIG. 14 Global market for Epogen by geography 2013 (% share) 48
FIG. 15 Global market for Levemir by geography 2013 (% share) 50
FIG. 16 Global market for Victoza by geography 2013 (% share) 52
FIG. 17 Global market for Betaseron by geography 2013 (% share) 54
FIG. 18 Global market for Neupogen by geography 2013 (% share) 56
FIG. 19 Global market for Eylea by geography 2013 (% share) 58
FIG. 20 Global market for Humira by geography 2013 (% share) 60
FIG. 21 Global market for Remicade by geography 2013 (% share) 63
FIG. 22 Global market for Rituxan by geography 2013 (% share) 65
FIG. 23 Global market for Avastin by geography 2013 (% share) 67
FIG. 24 Global market for Herceptin by geography 2013 (% share) 70
FIG. 25 Global market for Lucentis by geography 2013 (% share) 72
FIG. 26 Global market for Prevnar 13 by geography 2013 (% share) 74
FIG. 27 Global market for Gardasil by geography 2013 (% share) 77
FIG. 28 Global market for Fluzone by geography 2013 (% share) 79
FIG. 29 Global market for Varivax by geography 2013 (% share) 81
FIG. 30 Global market for Cervarix by geography 2013 (% share) 83
FIG. 31 North America market for biological drugs, by country, 2013 (% share) 86
FIG. 32 North America market for biological drugs, by therapeutic protein, 2013 (% share) 87
FIG. 33 North America market for biological drugs, by mAb, 2013 (% share) 90
FIG. 34 North America market for biological drugs, by vaccine, 2013 (% share) 92
FIG. 35 Europe market for biological drugs, by country, 2013 (% share) 94
FIG. 36 Europe market for biological drugs, by therapeutic protein, 2013 (% share) 96
FIG. 37 Europe market for biological drugs, by mAb, 2013 (% share) 99
FIG. 38 Europe market for biological drugs, by vaccine, 2013 (% share) 101
FIG. 39 Asia market for biological drugs, by country, 2013 (% share) 103
FIG. 40 Asia market for biological drugs, by therapeutic protein, 2013 (% share) 105
FIG. 41 Asia market for biological drugs, by mAb, 2013 (% share) 108
FIG. 42 Asia market for biological drugs, by vaccine, 2013 (% share) 110
FIG. 43 Competitive landscape of biological drugs market 117
FIG. 44 Pfizer revenue and net income, 2011–2013 (US$ Mn) 119
FIG. 45 Abbott net sales and net earnings, 2011–2013 (US$ Mn) 124
FIG. 46 Novartis net sales and net income, 2011–2013 (US$ Mn) 127
FIG. 47 Lilly revenue and net income, 2011–2013 (US$ Mn) 130
FIG. 48 GlaxoSmithKline turnover and profit, 2011–2013 (US$ Mn) 132
FIG. 49 Bristol-Myers Squibb revenue and net earnings, 2011–2013 (US$ Mn) 136
FIG. 50 Merck sales and net income, 2011–2013 (US$ Mn) 140
FIG. 51 Amgen revenue and net income, 2011–2013 (US$ Mn) 143
FIG. 52 Baxter net sales and net income, 2011–2013 (US$ Mn) 146
FIG. 53 Biogen Idec revenue and net income, 2011–2013 (US$ Mn) 150